A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL

Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab with or without Acalabrutinib in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab

Trial Details

NCT ID
NCT03571568
Phase
PHASE1 / PHASE2
Sponsor
BioInvent International AB
Status
RECRUITING
Cancer Type
Marginal Zone Lymphoma Lymphoma
Interventions
  • BI-1206
  • Rituximab
  • Acalabrutinib
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Louisville, Kentucky, United States|38.25424,-85.75941
  • Salvador, Estado de Bahia, Brazil|-12.97563,-38.49096
  • Porto Alegre, Rio Grande do Sul, Brazil|-30.03283,-51.23019
  • Curitiba, Brazil|-25.42778,-49.27306

Key Eligibility Criteria

  • Are ≥ 18 years of age by initiation of study treatment.
  • Have B-cell NHL proven by histology, with histological subtypes limited to follicular lymphoma (FL) (except FL grade 3B), MCL and marginal zone lym…
  • Have measurable nodal disease
  • Are willing to undergo lymph node biopsies or biopsies of other involved tissue

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Marginal Zone Lymphoma Lymphoma Trials on Trialify →